Progress in Medicinal Chemistry
Directeurs de Collection : Lawton G., Witty David R.
1. Structure Based Drug Design for G Protein-Coupled Receptors Miles Congreve, João M. Dias and Fiona H. Marshall 2. P2X7 Antagonists as Potential Therapeutic Agents for the Treatment of CNS Disorders Christa C. Chrovian, Jason C. Rech, Anindya Bhattacharya and Michael A. Letavic 3. g-Secretase Modulators: Current Status and Future Directions Adrian Hall and Toshal R. Patel 4. Recent Progress in the Discovery and Development of N-Type Calcium Channel Modulators for the Treatment of Pain Margaret S. Lee
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.
Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.
Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.
He is a founder of INMedD, a new medicines discovery social enterprise.
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. Davi
- Extended timely reviews of topics in medicinal chemistry
- Targets and technologies relevant to the discovery of tomorrow’s drugs
- Analyses of successful drug discovery programmes
Date de parution : 01-2014
Ouvrage de 216 p.
15x22.8 cm
Épuisé